| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cost of Revenue | $3.6M | — | -62.9% |
| R&D Expense | $5.8M | — | -64.0% |
| SG&A Expense | $5.1M | — | -9.0% |
| Operating Income | -$11.0M | — | +49.8% |
| Net Income | -$1.2M | — | +94.5% |
| EPS (Basic) | -$0.04 | — | +97.2% |
| EPS (Diluted) | -$0.04 | — | +97.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $14.1M | -50.7% | -71.0% |
| Current Assets | $20.3M | -41.4% | -61.8% |
| Total Assets | $21.2M | -40.8% | -63.2% |
| Current Liabilities | $9.0M | -31.8% | -27.1% |
| Total Liabilities | $17.8M | -43.8% | +15.8% |
| Stockholders' Equity | $3.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$14.5M | — | +36.3% |
| Investing Cash Flow | $4K | — | +0.0% |
| -92.0% |